Synlogic (NASDAQ:SYBX) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why

Synlogic, Inc. (NASDAQ:SYBX)’s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.42 and traded as low as $1.41. Synlogic shares last traded at $1.50, with a volume of 28,219 shares traded.

Synlogic Stock Down 1.8 %

The company has a market cap of $17.19 million, a price-to-earnings ratio of -0.35 and a beta of 0.80. The business has a 50-day simple moving average of $1.42 and a two-hundred day simple moving average of $1.47.

Synlogic (NASDAQ:SYBX) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.17. Synlogic had a negative return on equity of 207.84% and a negative net margin of 2,284.65%. As a group, equities analysts anticipate that Synlogic, Inc. will post -2.71 earnings per share for the current year.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.